Latest @ CSI.

View All
June 9, 2023
Conclusion of STEP Ahead into an RNA World Workshop 2023!
CSI Singapore, in collaboration with NUS Yong Loo Lin School of Medicine, recently concluded the successful “STEP Ahead into an RNA World 2023” workshop held between 29 and 30 May 2023...
Read More »
May 25, 2023
CSI Singapore @ AACR 2023
CSI Singapore recently exhibited at the American Association for Cancer Research (AACR) Annual Meeting 2023 – the 114th Annual Meeting of the AACR between April 14th to April 19th. Held...
Read More »

Press Release

View All
Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025)

Wan-Qin Chong, MBBS a ∙ Jia-Li Low, MBBS a ∙ Joshua K Tay, PhD b,d ∙ Thi Bich Uyen Le, BSca ∙ Grace Shi-Qing Goh, BSc g ∙ Kenneth Sooi, MBBS a ∙ Hui-Lin Teo, MBBS h ∙ Seng-Wee Cheo, MD a ∙ Regina Tong-Xin Wong, BSc g ∙ Jens Samol, MD h,j,k ∙ Ming-Yann Lim, MBBS i ∙ Hao Li, MBBS i ∙ Niranjan Shirgaonkar, MSc l ∙ Shumei Chia, PhD l ∙ Lingzhi Wang, PhD f,g ∙ Anil Gopinathan, MBBS c ∙ Donovan Kum-Chuen Eu, MBBS b ∙ Raymond King-Yin Tsang, MBChB b,d ∙ Prof Kwok-Seng Loh, MBBS b,d ∙ Prof Han-Chong Toh, MBBS m ∙ Nicholas Syn, MBBSe ∙ Li-Ren Kong, PhD f,g ∙ Ramanuj Dasgupta, PhD l ∙ Bee-Choo Tai, PhD n ∙ Yaw-Chyn Lim, PhD …

Pembrolizumab With or Without Bevacizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Open-Label, Phase 2 Trial (The Lancet Oncology, Feb 2025) Read More »

Follow Us on Twitter

Upcoming Events

View All
×

CSI Web Experience Survey Form

Please Rate Your Satisfaction

Overall Satisfaction For This Site:
Visual Appeal:
Ease Of Finding Information:
Relevance Of Information:
Readability Of Information:
Did you accomplish what you wanted to do today on this site?